FrançaisAre analysts right about Bio-Techne (TECH)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Bio-Techne, we replayed every analyst price target of the past 12 months and measured the real outcome: 40% were profitable, average return +12% (73 calls). At 3 months: +5% average return (58% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Baird | 10 | 40% | +8% |
| Stephens & Co. | 8 | 25% | +11% |
| Benchmark | 7 | 14% | -4% |
| Deutsche Bank | 6 | 67% | +23% |
| Citigroup | 6 | 67% | +22% |
Valuation
Is Bio-Techne overvalued, and is it a good time to buy Bio-Techne right now? If you're wondering, here's a recap to make up your own mind: Bio-Techne's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Bio-Techne | Sector median (Health Care) |
|---|---|---|
| P/E | 62.5 | 29.4 |
| Forward P/E | 31.3 | 17.1 |
| Net margin | 15% | 12% |
👉 Bio-Techne trades above its sector median (62.5 vs 29.4) — the market expects higher growth; watch out for disappointment.
📖 P/E, PEG, margin…: see the glossary
💵 Dividend : Bio-Techne pays about $0.32/share/yr → 0.45% yield. what is this?
Frequently asked questions
Is Bio-Techne a buy right now?
The analyst consensus on Bio-Techne (TECH) is "Hold" (12 bullish, 0 bearish calls over 12 months). This is not advice: historically, 40% of their targets on this stock turned out profitable over 1 year.
What is Bio-Techne's price target?
The median 12-month price target is $73.00 (+1% vs $72.47), ranging from $50.00 to $73.00 (8 analysts).
Are analysts accurate on Bio-Techne?
Over 1 year, 40% of analyst targets on Bio-Techne were profitable, for an average return of +12% (across 73 timestamped calls). This is JPI Invest's accuracy metric.
What is the Bio-Techne stock forecast?
Analysts target a median of $73.00 within 12 months, i.e. +1% vs the current price. The most bullish targets $73.00, the most cautious $50.00.
What is the Bio-Techne stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $73.00, +1%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (40%), and the stock's past trajectory.
Is Bio-Techne overvalued?
Its P/E is 62.5, forward P/E 31.3. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Bio-Techne →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.